Significant improvement of facial actinic keratoses after blue light photodynamic therapy with oral vitamin D pretreatment: An interventional cohort-controlled trial

Abstract

In mouse models of skin cancer, high-dose oral vitamin D3 (VD3; cholecalciferol) combined with photodynamic therapy (PDT) can improve the clearance of squamous precancers (actinic keratoses [AKs]). To determine whether oral VD3 can improve the clinical efficacy of a painless PDT regimen in humans with AK. The baseline lesion counts and serum 25-hydroxyvitamin D3 levels were determined. In group 1, 29 patients underwent gentle debridement and 15-minute aminolevulinic acid preincubation with blue light (30minutes; 20J/cm2). In group 2, 29 patients took oral VD3 (10,000 IU daily for 5 or 14days) prior to debridement and PDT. Lesion clearance was assessed at 3 to 6months. In group 1, the mean clearance rates of facial AK were lower in patients with VD3 deficiency (25-hydroxyvitamin D3 level < 31ng/dL; clearance rate, 40.9%±42%) than in patients with normal 25-hydroxyvitamin D3 levels (62.6%±14.2%). High-dose VD3 supplementation (group 2) significantly improved the overall AK lesion response (72.5%±13.6%) compared with that in group 1 (54.4%±22.8%). No differences in side effects were noted. Nonrandomized trial design (interventional cohort matched to registry-based controls). Oral VD3 pretreatment significantly improves AK clinical responses to PDT. The regimen appears promising and well tolerated.